103 related articles for article (PubMed ID: 24083612)
1. HIV-1 inhibiting capacity of novel forms of presentation of GB virus C peptide domains is enhanced by coordination to gold compounds.
Gómara MJ; Galatola R; Gutiérrez A; Gimeno MC; Gatell JM; Sánchez-Merino V; Yuste E; Haro I
Curr Med Chem; 2014; 21(2):238-50. PubMed ID: 24083612
[TBL] [Abstract][Full Text] [Related]
2. A cyclic GB virus C derived peptide with anti-HIV-1 activity targets the fusion peptide of HIV-1.
Galatola R; Vasconcelos A; Pérez Y; Cruz A; Pujol M; Alsina MA; Gómara MJ; Haro I
Eur J Med Chem; 2014 Oct; 86():589-604. PubMed ID: 25218908
[TBL] [Abstract][Full Text] [Related]
3. Synthetic peptides derived from an N-terminal domain of the E2 protein of GB virus C in the study of GBV-C/HIV-1 co-infection.
Fernández L; Chan WC; Egido M; Gómara MJ; Haro I
J Pept Sci; 2012 May; 18(5):326-35. PubMed ID: 22438139
[TBL] [Abstract][Full Text] [Related]
4. Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.
Gómara MJ; Sánchez-Merino V; Paús A; Merino-Mansilla A; Gatell JM; Yuste E; Haro I
Biochim Biophys Acta; 2016 Jun; 1860(6):1139-48. PubMed ID: 26905802
[TBL] [Abstract][Full Text] [Related]
5. Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.
Herrera E; Gomara MJ; Mazzini S; Ragg E; Haro I
J Phys Chem B; 2009 May; 113(20):7383-91. PubMed ID: 19402654
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 fusion is blocked through binding of GB Virus C E2-derived peptides to the HIV-1 gp41 disulfide loop [corrected].
Eissmann K; Mueller S; Sticht H; Jung S; Zou P; Jiang S; Gross A; Eichler J; Fleckenstein B; Reil H
PLoS One; 2013; 8(1):e54452. PubMed ID: 23349893
[TBL] [Abstract][Full Text] [Related]
7. Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.
Herrera E; Tenckhoff S; Gómara MJ; Galatola R; Bleda MJ; Gil C; Ercilla G; Gatell JM; Tillmann HL; Haro I
J Med Chem; 2010 Aug; 53(16):6054-63. PubMed ID: 20718496
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a peptide domain within the GB virus C envelope glycoprotein (E2) that inhibits HIV replication.
Xiang J; McLinden JH; Kaufman TM; Mohr EL; Bhattarai N; Chang Q; Stapleton JT
Virology; 2012 Aug; 430(1):53-62. PubMed ID: 22608061
[TBL] [Abstract][Full Text] [Related]
9. GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates.
Mohr EL; Xiang J; McLinden JH; Kaufman TM; Chang Q; Montefiori DC; Klinzman D; Stapleton JT
J Immunol; 2010 Oct; 185(7):4496-505. PubMed ID: 20826757
[TBL] [Abstract][Full Text] [Related]
10. Chimpanzee GB virus C and GB virus A E2 envelope glycoproteins contain a peptide motif that inhibits human immunodeficiency virus type 1 replication in human CD4⁺ T-cells.
McLinden JH; Stapleton JT; Klinzman D; Murthy KK; Chang Q; Kaufman TM; Bhattarai N; Xiang J
J Gen Virol; 2013 Apr; 94(Pt 4):774-782. PubMed ID: 23288422
[TBL] [Abstract][Full Text] [Related]
11. Liposome destabilization induced by synthetic lipopeptides corresponding to envelope and non-structural domains of GBV-C/HGV virus. Conformational requirements for leakage.
Fernández-Vidal M; Rojo N; Herrera E; Gómara MJ; Haro I
Biophys Chem; 2008 Jan; 132(1):55-63. PubMed ID: 17988786
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a peptide domain within the GB virus C NS5A phosphoprotein that inhibits HIV replication.
Xiang J; McLinden JH; Chang Q; Jordan EL; Stapleton JT
PLoS One; 2008 Jul; 3(7):e2580. PubMed ID: 18596910
[TBL] [Abstract][Full Text] [Related]
13. Biophysical investigations of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide.
Sánchez-Martín MJ; Urbán P; Pujol M; Haro I; Alsina MA; Busquets MA
Chemphyschem; 2011 Oct; 12(15):2816-22. PubMed ID: 21905195
[TBL] [Abstract][Full Text] [Related]
14. Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.
Koedel Y; Eissmann K; Wend H; Fleckenstein B; Reil H
J Virol; 2011 Jul; 85(14):7037-47. PubMed ID: 21543477
[TBL] [Abstract][Full Text] [Related]
15. Influence of hepatitis G virus (GB virus C) on the prognosis of HIV-infected women.
Campos AF; Tengan FM; Silva SA; Levi JE
Int J STD AIDS; 2011 Apr; 22(4):209-13. PubMed ID: 21515753
[TBL] [Abstract][Full Text] [Related]
16. Surface behavior of peptides from E1 GBV-C protein: Interaction with anionic model membranes and importance in HIV-1 FP inhibition.
Galatola R; Cruz A; Gómara MJ; Prat J; Alsina MA; Haro I; Pujol M
Biochim Biophys Acta; 2015 Feb; 1848(2):392-407. PubMed ID: 25450346
[TBL] [Abstract][Full Text] [Related]
17. Assessment of synthetic chimeric multiple antigenic peptides for diagnosis of GB virus C infection.
Gómara MJ; Fernández L; Pérez T; Ercilla G; Haro I
Anal Biochem; 2010 Jan; 396(1):51-8. PubMed ID: 19751699
[TBL] [Abstract][Full Text] [Related]
18. Modification of FP-HIV activity by peptide sequences of GB virus C: a biophysical approach.
Domènech O; Ortiz A; Pujol M; Haro I; Muñoz M; Alsina MA; Prat J; Busquets MA; Girona V
Biochim Biophys Acta; 2014 May; 1838(5):1274-80. PubMed ID: 24530897
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of anti-GBV-C antibodies in HIV-infected patients.
Gómara MJ; Fernández L; Pérez T; Tenckhoff S; Casanovas A; Tillmann HL; Haro I
Chem Biol Drug Des; 2011 Aug; 78(2):277-82. PubMed ID: 21599855
[TBL] [Abstract][Full Text] [Related]
20. GB virus C: insights into co-infection.
Berzsenyi MD; Bowden DS; Roberts SK
J Clin Virol; 2005 Aug; 33(4):257-66. PubMed ID: 15922655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
